SIM
ZNTL icon

Sandia Investment Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Sandia Investment Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,500
Closed -$43K – 275
2023
Q1 		$43K Sell
2,500
-2,500
-50% -$50.6K 0.01% 201
2022
Q4 		$101K Hold
5,000
– – 0.02% 165
2022
Q3 		$108K Buy
+5,000
New +$137K 0.02% 195

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sandia Investment Management's ZNTL Position: Q2 2023 in Review

Sandia Investment Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2023, closing a stake of 2,500 shares — an estimated $43K sold.

Sandia Investment Management first reported a position in ZNTL in Q3 2022 and held it in 3 quarters. The position peaked at $108K in Q3 2022. 134 funds tracked by Wall St. Rank hold ZNTL as of Q2 2023.

  • Sandia Investment Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Sandia Investment Management sold 2,500 Zentalis Pharmaceuticals shares in Q2 2023, an estimated $43K.
  • Sandia Investment Management first reported a position in Zentalis Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Sandia Investment Management's Zentalis Pharmaceuticals position peaked at $108K in Q3 2022.
  • 134 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2023.

Based on Sandia Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.